



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



⑪ Publication number : **0 477 050 A2**

⑫

## EUROPEAN PATENT APPLICATION

⑬ Application number : **91402275.1**

⑭ Date of filing : **20.08.91**

⑮ Int. Cl.<sup>5</sup> : **C12N 1/20, C12P 19/04,  
A61K 37/22, // (C12N1/20,  
C12R1:01)**

The microorganism(s) has (have) been deposited with Fermentation Research Inst. Agency of Ind. Science on Technology under numbers FERM P-11664, FERM P-11665, FERM P-11666 and transferred to the Intern. deposit under Budapest Treaty on August 12, '91 under no. FERM BP-3509, FERM BP-3510, FERM BP-3511.

⑯ Priority : **20.08.90 JP 218599/90  
20.11.90 JP 312932/90**

⑰ Date of publication of application : **25.03.92 Bulletin 92/13**

⑲ Designated Contracting States :  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

⑳ Applicant : **CHIBA FLOUR MILLING CO. LTD.  
17, Shinko  
Chiba City, Chiba (JP)**

㉑ Applicant : **Soma, Gen-Ichiro  
1-10-21, Higashi-Tamagawa  
Setagaya Ward, Tokyo (JP)**

㉒ Applicant : **Mizuno, Den'ichi  
18 Okamoto  
Kamakura City, Kanagawa (JP)**

㉓ Inventor : **Soma, Gen-Ichiro  
1-10-21, Higashi-Tamagawa  
Setagaya Ward, Tokyo (JP)  
Inventor : Yoshimura, Kiyoshi  
3-26-7, Isobe  
Chiba City, Chiba (JP)  
Inventor : Takioka, Daisuke  
1-21-17, Kasuga  
Chiba City, Chiba (JP)  
Inventor : Mizuno, Den'ichi  
Okamoto-18  
Kamakura City, Kanagawa (JP)  
Inventor : Oshima, Haruyuki  
2-10-513, Tate-machi 1097, Hachioji City  
Tokyo (JP)**

㉔ Representative : **Schriftpf, Robert et al  
Cabinet Regimbeau 26, Avenue Kléber  
F-75116 Paris (FR)**

㉕ **LPS-producing bacteria, LPSs, and LPS-containing medicines and veterinary medicines.**

㉖ Novel LPS having the following physical properties, novel bacilli providing those LPS, and novel immunity stimulators, analgesics, and antiwithdrawal agents, and novel veterinary immunity stimulators, analgesics, and antiwithdrawal agents containing LPS selected from the group consisting of those LPSs and mixtures thereof.

LPS1

Dominant molecular weight :

5,000 ± 1,000 as determined by SDS-PAGE method

Phosphorus number :

2 ± 1 / 5,000 (m.w.)

Hexosamine number :

9 ± 1 / 5,000 (m.w.)

KDO number :

2 ± 1 / 5,000 (m.w.)

LPS2

Dominant molecular weight :

6,500 ± 2,500 as determined by SDS-PAGE method

Phosphorus number :

1 to 2 / 5,000 (m.w.)

Hexosamine number :

7 ± 1 / 5,000 (m.w.)

KDO number :

1 to 2 / 5,000 (m.w.)

LPS3

Dominant molecular weight :

**EP 0 477 050 A2**

**6,500 ± 2,500 as determined by SDS-PAGE method**  
**Phosphorus number :**  
**2 ± 1 / 5,000 (m.w.)**  
**Hexosamine number :**  
**5 ± 1 / 5,000 (m.w.)**  
**KDO number :**  
**2 ± 1 / 5,000 (m.w.)**

## Field of the invention

The present invention relates to novel LPS-producing bacteria, novel LPSS, and LPS-containing medicines and veterinary medicines.

5 More particularly, it is concerned with three novel glucose-fermentative gram-negative small bacilli which produce LPSs, novel LPSs provided by those bacteria, and novel immunity-stimulating agents, analgesics, anti-withdrawal agents, veterinary immunity-stimulating agents, veterinary analgesics and veterinary antiwithdrawal agents containing those LPSs.

## 10 Description of the prior art

Organisms have their own immunity to keep their internal conditions from being disturbed by exogenous or endogenous matter and to maintain their homeostasis. Thus, the lowering of immunity causes deterioration of health, occurrence of various diseases, stimulation of aging, etc. On the other hand, its activation leads to improvement of health, prevention against occurrence of various diseases, cure of various diseases and prevention of aging or the like.

15 For the above-mentioned, it has been desired to provide a substance capable of activating immunity. To date, PSK [another name: Krestin<sup>R</sup> (trade name of Kureha Kagaku Co. in Japan and registered in Japan), Len-tinan<sup>R</sup> (trade name of Ajinomoto Co. in Japan and registered in Japan), Bestatin<sup>R</sup> (trade name of Nihon Kayaku Co. in Japan and registered in Japan), Sonifilan<sup>R</sup> (trade name of Kaken Seiyaku Co. in Japan and registered in Japan), OK-432 (*Cancer Chemotherapy Reports Part 1*, vol. 58, No. 1, p. 10, 1972; another name: Picibanil<sup>R</sup> (trade name of Chugai Seiyaku Co. in Japan and registered in Japan), etc. are known to have such capability.

Analgesics are classified into two groups; narcotic and non-narcotic ones.

20 Narcotic analgesics are of course narcotics, and thus they are required to be administered with the greatest care. (*Clinical pains*, pp. 70 - 74, 1981, *Medical Friend Co. in Japan*)

25 On the other hand, generally the analgesic action of non-narcotic analgesics is characterized to be less than that of narcotic ones and to be nonhabit-forming. But, actually their prolonged use is reported to cause tolerance and/or dependence of the patients thereto, and thus they are considered to be used in the same manner as narcotic-ones from pharmacological viewpoints. (*Clinical pains*, p. 74, *supra*)

30 It is generally well known that the so-called withdrawal symptom occurs when one is suddenly kept from taking alcohol, morphinic narcotics, nicotine, etc. to which he has become addicted. Also it is well known that addicts of them are hard to return to daily life, and the clinical use of narcotics is restricted because of withdrawal symptoms.

35 To date, methadone, clonidine, dizocilpine, etc. are known as medicines for suppressing such withdrawal symptoms. Methadone is, however, reported to cause dependence to itself. (P. R. Dougherty, et al., "Neuropharmacology", 26, pp. 1595 - 1600, 1987) Clonidine is reported to suppress withdrawal body shake by intraperitoneal administration of 0.16 mg/kg. (*Stuart Fielding, et al. The Journal of Pharmacology and Experimental Therapeutics*, vol. 207, No. 7, pp. 899 - 905, 1978) But, we, the inventors, have found that intravenous administration of clonidine fails to suppress jumping, a severer withdrawal symptom even at a dose of 0.1 - 10 mg/kg, and further causes convulsions at a dose of 10 mg/kg. Dizocilpine shows only an extremely small difference between its toxic and effective doses, and thus is not safe. (Keith A., et al., "Science", 251, pp. 85 - 87, 1991)

40 Of the prior art immunity stimulators, PSK, Lentinan<sup>R</sup>, Bestatin<sup>R</sup> and Sonifilan<sup>R</sup> have no TNF productivity, and thus their immunity stimulation is poor.

45 Surely OK-432 is known to have TNF productivity, but a rather large quantity of it must be administered to produce a satisfactory quantity of TNF, thereby inevitably causing attack of fever or rigor, lowering of blood pressure, and reduction in the number of thrombocytes. Accordingly, OK-432 has a low therapeutic range. OK-432 has an additional drawback in that its production steps include culture of microorganisms, and extremely complicated procedures for its separation and purification to increase the production cost. Further, OK-432 fails to produce TNF through oral or subcutaneous administration which is very convenient for medication; therefore OK-432 must be administered by inconvenient means.

50 Here, the term "TNF" is the generic name for tumor necrosis factors produced by macrophage (*The Journal of Biol. Chem.*, 260, pp. 2345-2354, 1985), and the production quantity of TNF increases depending on the activity of macrophage. Macrophage is the generic name for large amoeba-like cells which belong to immunocompetent cells, are present in most internal tissues of animals, and prey and digest particulate foreign matter and waste cells in the body. The term "therapeutic range" is the ratio of the maximum tolerable dose of the host to the medicine to the minimum effective dose of the medicine; the larger the ratio is, the better the medicine is.

As mentioned above, the prior art analgesics have drawbacks, and no satisfactory ones have not been provided yet. Particularly, analgesics which are effective against chronic pain, are highly safe, have no side effects, are cheap and are very convenient for medication have been greatly expected to be developed. Also no satisfactory antiwithdrawal agents have not been provided yet.

5 The present invention is intended to provide novel immunity-stimulating agents, analgesic agents, antiwithdrawal agents, veterinary immunity-stimulating agents, veterinary analgesic agents and veterinary antiwithdrawal agents which are free from the drawbacks of the prior art.

10 An additional object of the present invention is to provide novel LPSs, active ingredients of those agents, which have excellent immunity-stimulating, analgesic and antiwithdrawal effects, show a high therapeutic range, and may be provided at a low cost and in a large amount and may be administered via any route of oral and intradermal administration and injection.

15 An additional object of the present invention is to provide novel bacteria which produce the novel LPSs.

#### Brief description of the drawings

15 Fig. 1 is a chart showing the patterns of the LPSs of the present invention on SDS-PAGE method.

Fig. 2 is a graph showing the analgesic effects of the LPSs of the present invention in comparison with E. coli LPS.

20 Fig. 3 is a graph showing the dose-dependent antiwithdrawal effects of the LPSs of the present invention in Intravenous administration.

Fig. 4 is a graph showing the dose-dependent antiwithdrawal effects of the LPSs of the present invention in subcutaneous administration.

Fig. 5 is a graph showing the administration time-dependent withdrawal-preventive effects of the LPSs of the present invention.

#### 25 Detailed description of the invention

##### Bacteria-providing sources

30 The three bacteria according to the present invention were isolated from all kinds of wheat investigated by the inventors of the present invention regardless of their places of production. Thus, those bacteria are supposed to be isolated from any kind of wheat produced in any place and its processed goods. The kinds and the places of production of the wheat flour from which the three bacteria mentioned above were confirmed to be isolated by the inventors of the present invention include the following:

	<u>Kinds of wheat flour</u>	<u>Places of production</u>
	Dark Northern Springs	U.S.A.
	1 Canadian Wheat	Canada
	Hard Red Winter Semi-hard	U.S.A.
	Australian Standard Wheat	Australia
40	Horoshiri	Japan

##### Isolation of LPSs

45 The LPSs of the present invention may be isolated from the above bacteria by the hot phenol process described on page 83 of Westphal, et al., "Methods in Carbohydrate Chemistry", vol. v, 1965, Academic press in New York, followed by purification on an anion-exchange resin.

That is, the cells are suspended in distilled water which is then stirred with an equimolar of hot phenol. Next, the aqueous layer is recovered by centrifugation and then subjected to dialysis to remove off the phenol. The aqueous layer is concentrated by ultrafiltration to yield crude LPS fractions which are then purified conventionally, for example, by anion-exchange chromatography using mono Q-Sepharose and Q-Sepharose in FPLC system (all manufactured by Pharmacia Inc.), followed by desalting in a conventional manner.

50 Products of 96% or more purity are provided by the foregoing procedures.

##### Physical properties of LPSs

55 As explained in detail in the examples given later, the three LPSs of the present invention having a purity of 96% or more showed the following physical properties ("SDS-PAGE method will be defined later in Example 1):

	LPS1
	Dominant molecular weight: 5,000 ± 1,000 as determined by SDS-PAGE method
	Phosphorus number: 2 ± 1 / 5,000 (m.w.)
	Hexosamine number: 9 ± 1 / 5,000 (m.w.)
5	KDO number: 2 ± 1 / 5,000 (m.w.)
	LPS2
	Dominant molecular weight: 6,500 ± 2,500 as determined by SDS-PAGE method
	Phosphorus number: 1 to 2 / 5,000 (m.w.)
	Hexosamine number: 7 ± 1 / 5,000 (m.w.)
10	KDO number: 1 to 2 / 5,000 (m.w.)
	LPS3
	Dominant molecular weight: 6,500 ± 2,500 as determined by SDS-PAGE method
	Phosphorus number: 2 ± 1 / 5,000 (m.w.)
	Hexosamine number: 5 ± 1 / 5,000 (m.w.)
15	KDO number: 2 ± 1 / 5,000 (m.w.)

#### Forms supplied

20 The LPSs of the present invention may be supplied as such or in forms concentrated to any desired degree. Further, they may be supplied as dry powders by any of the conventional manners including lyophilization and spray drying to improve stability. Any of these forms may be produced conventionally.

#### Determination of immunity stimulation

25 The immunity stimulation of the LPSs according to the present invention has been confirmed by endogenous TNF productivity.

Carswell et al. report that priming and triggering steps are necessary to produce endogenous TNF in the body of an animal; see *Proc. Natl. Acad. Sci. USA.*, 72, pp. 3666 - 3670, 1975. Thereafter, many candidate chemicals were tried to stimulate the respective steps. The chemical used to start the priming step is a primer (endogenous TNF production stimulator), while that administered to start the triggering step is a trigger (endogenous TNF productive agent).

30 The TNF activity is determined, as follows, on the basis of the cytotoxicity to L929 cells (*Proc. Natl. Acad. Sci. U.S.A.*, 72, pp. 3666 - 3670, 1975). L-929 cells are cultured in Eagles' Minimum Essential Medium (hereunder referred to only as MEM) with 5 % fetal calf serum (hereunder referred to only as FCS) added thereto until 100 µl of the medium contains  $8 \times 10^4$  cells, and then the cells are grown in a flat-bottomed plate having 96 wells.

35 The growth conditions are 37°C in the presence of 5 % CO<sub>2</sub>, and under a humidity of 100 % for 2 hours, and the procedures may be the same as for the conventional cell culture. Then actinomycin D is added to the medium to a final concentration of 1 µg/ml, and the volume of the culture solution is adjusted to 150 µl. Immediately thereafter 50 µl of the sample diluted appropriately with MEM medium is added to the culture solution. Here, ED<sub>50</sub> may be determined by adjusting the dilution appropriately. The L-929 cells having a final volume of 200 µl are cultured for an additional 18 hours under the same conditions as described above.

40 In order to determine the cell necrosis activity, first the whole medium is removed followed by addition of a 1% methyl alcoholic solution containing 0.1 % crystal violet for fixation staining. Crystal violet stains all the eukaryotic cells, but the dead cells are removed off from the bottom of the flask only by washing after the staining; so the cell necrosis activity may be determined directly. The staining degree is measured on the basis of adsorption at OD<sub>590nm</sub>, and is compared with that of a control to determine the cell necrosis activity. This activity is defined as follows.

45 The dilution of the sample which allows 50 % of the L-929 cells to survive (N) is determined. Rabbit TNS is used as the control, and its activity n (units/ml) is determined using  $2.4 \times 10^6$  units/mg/ml of TNF-α. The dilution which provides ED<sub>50</sub> of rabbit TNS is determined.

50 The activity of the sample (units/ml) is calculated by the equation: N/C x n.

#### Determination of analgesic effects

55 The analgesic effects of the LPSs of the present invention have been confirmed by an experiment using animals according to the acetic acid-writhing method described on page 415 of "Inflammation and anti-inflammatory therapy" issued in 1982 by Ishiyaku Shuppan Co. in Japan, one of the established methods for the deter-

mination of the effects of non-narcotic analgesics.

Determination of antiwithdrawal effects

5 The antiwithdrawal effects of the LPSs according to the present invention have been confirmed by the reduction in the frequency of jumping, the severest withdrawal symptom caused by the administration of naloxone to morphine-addictive mice. Naloxone is available from Endo Labs. Inc. in U.S.A., and is known to be a morphine antagonist; "The Journal of Pharmacology and Experimental Therapeutics", vol. 207, No. 7, p. 901, *supra*.

10 The LPSs according to the present invention may be used separately, and further may be used in admixture with each other or together with any other substance so far as the intended effects are not made less. In addition, they may be ingredients of immunity diagnosis reagents, veterinary immunity diagnostic reagents, quasi drugs defined in the Japanese Pharmacopoeia, cosmetics, food, drinks and feed.

15 Any of the above preparations including immunity stimulators may be produced conventionally. For example, in the conventional manner of preparing medicines or veterinary medicines, they may be supplied conventionally in the form of powders, granules, pills, tablets, troches, capsules, solutions, pastes, ointments, liniments, lotions, suppositories, injections, etc. Particularly, many macrophages are present in the skin, so the LPSs of the present invention may be prepared as skin ointments in order to obtain better effects. For veterinary use, also the agents may be prepared in the form of feed additives, premix preparations, drinking water additives. Here, the "premix preparations" are such preparations as contain feed components beforehand so that they are easily mixed in the feed. The feed additives are preferred to be powders or granules. Any commercially available feed may be used to prepare the above-mentioned feed additives, premix preparations, etc. The feed may contain minerals, vitamins, amino acids and any other feed additives.

20 If desired, these preparations may contain excipients, preservatives, buffers, etc. conventionally to improve the shelf life, homogeneity, etc. In addition, the preparations may contain correctives to improve taste, odor, appearance, etc. The excipients include, for example, lactose, starch, etc. The preservatives include, for example, parahydroxybenzolic esters such as methyl, ethyl or propyl paraoxybenzoate, sodium dehydroacetate, phenols, methyl, ethyl or propylparabene, etc. The buffers include, for example, citric, acetic or phosphoric acid salts, etc.

25 30 Hereunder, the present invention will be explained in detail with reference to examples, preparations and experiments. The *E.coli* LPS used therein is one available from Difco Co. in U.S.A. under the code number of 0128:B8

Example 1

35 1) In a 50 ml coning tube, there was charged 1.04 g of hard flour containing 1.09% of ash (1 Canadian wheat from Canada) followed by addition of 20ml of distilled water thereto to prepare a 50 mg/ml aqueous solution of wheat flour.

40 2) The solution was cultured in a water bath at 37°C while shaking, and 0.5 ml portions of the solutions were collected at 0, 1, 2, 3, 4, 6, 8, 10, 12, 20, 24 and 45 hours thereafter. 100 µl portions of the respective solutions diluted to 1 to 100,000 times were taken in standard agar culture media available from Nissui Seiyaku Co. in Japan and having the following composition to determine the number of living cells and to observe the colonies.

45 Standard agar culture media (Nissui Seiyaku's code No.: 05618)

Yeast extracts	2.5 g/l
Peptone	5.0 g/l
Glucose	1.0 g/l
Agar	15.0 g/l
pH	7.1±0.1

50 At the end of 8 and 10 hour culture, yellow to creamy opaque colony (colony 1), creamy opaque colony (colony 2) yellow translucent colony (colony 3), milk white opaque colony (colony 4), and white opaque small colony (colony 5), which were judged to be different from each other, were scattered on the respective standard agar culture having the same composition as the above, for subcultivation. The gram staining and limulus activity of the bacteria in the colonies were determined.

55 Here, the "limulus activity" means to be positive to limulus test which is a method invented by Levin in 1968 for quantitative determination of endotoxin using a horseshoe crab haemocyte extract and a chromogenic sub-

strate. The limulus test is known as a method for the detection of LPSs, and may be carried out using, for example, a reagent set commercially available from Sei-Kagaku Kogyo Co. in Japan under the trade name of Toxi Color system.

5 Of the above colonies, the limulus activity of the colonies 4 and 5 (both being gram stain-positive) were extremely low as compared with that of the colonies 1, 2 and 3 (all being gram stain-negative), so the former colonies were taken aside. The morphological and biochemical characteristics of only the colonies 1, 2 and 3 were observed using the media available from Nissui Selyaku Co. and ID tests EB-20 to show the following results:

10 **Bacteria forming the colony 1 (ID number: 900814-1)**

(The bacteria were deposited with Fermentation Research Institute Agency of Industrial Science and Technology on August 17, 1990 under the number of FERM P-11664 and transferred to the International deposit under BUDAPEST TREATY on August 12, 1991 under the number of FERM BP-3509.)

15 The bacteria are supposed to belong to the genus *Serratia* of the family Enterobacteriaceae in view of the following morphological and biochemical characteristics.

a) Morphological characteristics

- 1) Small rod
- 2) No Motility
- 3) Gram stain: -

b) Growth

- 1) Standard agar medium: a yellow to creamy round opaque colony is formed.
- 2) SS agar medium: A white translucent colony is formed.

[SS agar medium: Nissui Selyaku's code No. 05031]

25

Broth 5.0 g/l

30

Bile acid salts 9.0 g/l

Peptone 7.5 g/l

Lactose 10.0 g/l

35

Sodium citrate 8.5 g/l

Sodium thiosulfate 5.5 g/l

40

Ferric citrate 1.0 g/l

Neutral red 0.025 g/l

45

Brilliant green 0.033 g/l

Agar 13.5 g/l

pH: 7.1 ± 0.1

50

3) TSI agar medium: No change is found on the slant, but the higher layer changes to yellow. Gas is produced.

[SS agar medium: Nissui Selyaku's code No. 05031]

55

	<b>Broth</b>	<b>5.0 g/l</b>
5	<b>NaCl</b>	<b>5.0 g/l</b>
	<b>Peptone</b>	<b>15.0 g/l</b>
	<b>Lactose</b>	<b>10.0 g/l</b>
10	<b>Sucrose</b>	<b>10.0 g/l</b>
	<b>Glucose</b>	<b>1.0 g/l</b>
15	<b>Ferric citrate</b>	<b>0.2 g/l</b>
	<b>Sodium thiosulfate</b>	<b>0.2 g/l</b>
	<b>Phenol red</b>	<b>0.02 g/l</b>
20	<b>Agar</b>	<b>15.0 g/l</b>

**pH: 7.6±0.1**

c) Physiological characteristics

25 1) Voges-Proskauer reaction: +  
 2) Indole production: -  
 3) Hydrogen sulfide production: -  
 4) Utilization of citrate: +  
 5) Urease: -  
 30 6) Oxidase: -  
 7) O-F test: +

d) Utilization of carbon sources

35 1) Lactose: +  
 2) Adonitol: -  
 3) Rhamnose: +  
 4) Mannitol: +  
 5) Esculin: +  
 6) Inositol: -  
 7) Sorbitol: +  
 40 8) Arabinose: +  
 9) Raffinose: +  
 10) Sucrose: +

e) Others

45 1) Lysin decarboxylase: -  
 2) Utilization of malonate: -  
 3) Arginine dihydroxylase: -  
 4) Phenylalanine deaminase: -  
 5) Ornithine decarboxylase: -

50 **Bacteria forming the colony 2 (ID number: 900814-2)**

(The bacteria were deposited with fermentation Research Institute Agency of Industrial Science and Technology on August 17, 1990 under the number of FERM P-11665 and transferred to the international deposit under BUDAPEST TREATY on August 12, 1991 under the number of FERM BP-3510.)

55 The bacteria are supposed to belong to the genus *Enterobacter* of the family Enterobacteriaceae in view of the following morphological and biochemical characteristics.

a) Morphological characteristics

1) Small rod

2) No Motility  
3) Gram stain: -

b) Growth

5 1) Standard agar medium: a creamy opaque colony is formed.  
2) SS agar medium: A red opaque colony is formed.  
3) TSI agar medium: No change is found on the slant, but the higher layer changes to yellow. Gas if produced.

c) Physiological characteristics

10 1) Voges-Proskauer reaction: + ,  
2) Indole production: -  
3) Hydrogen sulfide production: -  
4) Utilization of citrate: +  
5) Urease: -  
6) Oxidase: -  
15 7) O-F test: +

d) Utilization of carbon sources

20 1) Lactose: +  
2) Adonitol: -  
3) Rhamnose: +  
4) Mannitol: +  
5) Esculin: +  
6) Inositol: -  
7) Sorbitol: +  
8) Arabinose: +  
25 9) Raffinose: +  
10) Sucrose: +

e) Others

30 1) Lysin decarboxylase: -  
2) Utilization of malonate: +  
3) Arginine dihydroxylase: +  
4) Phenylalanine deaminase: -  
5) Ornithine decarboxylase: +

Bacteria forming the colony 3 (ID number: 900814-S)

(The bacteria were deposited with Fermentation Research Institute Agency of Industrial Science and Technology on August 17, 1990 under the number of FERM P-11666 and transferred to the international deposit under BUDAPEST TREATY on August 12, 1991 under the number of FERM BP-3511.)

The bacteria are supposed to belong to the genus *Pantoea* of the family *Enterobacteriaceae* in view of the following morphological and biochemical characteristics.

a) Morphological characteristics

40 1) Small rod  
2) No Motility  
3) Gram stain: -

b) Growth

45 1) Standard agar medium: A yellow round translucent colony is formed.  
2) SS agar medium: No colony is formed.  
3) TSI agar medium: No change is found on the slant, but the higher layer changes to yellow. Gas if not produced.

c) Physiological characteristics

50 1) Voges-Proskauer reaction: +  
2) Indole production: -  
3) Hydrogen sulfide production: -  
4) Utilization of citrate: +  
5) Urease: -  
55 6) Oxidase: -  
7) O-F test: +

d) Utilization of carbon sources

1) Lactose: +  
 2) Adonitol: -  
 3) Rhamnose: +  
 4) Mannitol: +  
 5) Esculin: +  
 6) Inositol: -  
 7) Sorbitol: +  
 8) Arabinose: +  
 9) Raffinose: -  
 10) Sucrose: +  
 5  
 e) Others  
 1) Lysin decarboxylase: -  
 2) Utilization of malonate: +  
 3) Arginine dihydroxylase: -  
 15 4) Phenylalanine deaminase: -  
 5) Ornithine decarboxylase: -  
 4) The colonies 1, 2 and 3 were transferred to 1 liter L-broth medium, respectively, and the media were  
 shaken at 37°C over night, and then subjected to centrifugation at 5,000 G, 4°C for 20 minutes to collect  
 the cells. The L-broth was prepared by dissolving 10 g of polypeptone (Difco Co.), 5 g of yeast extracts  
 (Difco Co.) and special grade NaCl (Wako-Jun-Yaku Co. in Japan) in distilled water, adjusting the pH of  
 the solution to 7.5 with NaOH followed by autoclaving, and then adding a 400-fold diluent of a 40% solution  
 of special grade glucose (Wako-Jun-Yaku Co.) to the solution.  
 20 5) The cells of the respective colonies were suspended in 50 ml of distilled water, and 50 ml of a 90 % hot  
 phenol was added to the suspension followed by stirring at 65 - 70°C for 20 minutes. After being cooled,  
 25 the mixture was subject to centrifugation at 10,000 G, 4°C for 20 minutes to recover the aqueous layer.  
 The phenol layer was treated additional two times in the same manner as the above. The combined three  
 aqueous layers were subjected to dialysis overnight to remove the phenol. The inner solution was subjected  
 to ultrafiltration using UK-20 (Advantec Toyo Co.) for concentration by cutting off molecular weight 200,000;  
 N<sub>2</sub> pressure: 2 atms.  
 30 6) The concentrated sample was subjected to anion-exchange chromatography using Q-Sepharose Fast  
 Flow (Pharmacia Co.). That is, the sample was applied to the column using a buffer solution containing 10  
 mM Tris-HCl (pH 7.5) and 10 mM of NaCl, and then the limulus active fractions were eluted with 400 mM  
 NaCl / 10mM Tris-HCl (pH 7.5). The eluate was subjected to ultrafiltration unde the same conditions as  
 35 the above for desalting and concentration to produce 96% or more pure LPS. The nucleic acid was eluted  
 with 1 M NaCl / 10 mM Tris-HCl (pH 7.5).  
 The results of the respective cells are shown in Tables 1 - 3. Here, the LPS content is in terms of E. coli  
 LPS. The sugar content was determined according to the phenol - sulfuric acid method (M. Dubis et al., "Analyti-  
 cal Chemistry", vol. 28, p. 350, 1956), while the protein content was determined by the Lowry method (O.H.  
 40 Lowry et al., "Journal of Biological Chemistry", vol. 193, p. 65, 1951). The nucleic acid content was determined  
 on the basis of the measurements of OD at 260 nm (1 OD= 50 µg), and the purity (%) was calculated by the  
 equation:  
 45

$$\text{Purity} = \frac{\text{Dried yield} - (\text{Protein yield} + \text{nucleic acid yield})}{\text{dried Yield}} \times 100$$

45 Table 1: 900814-1

	Total dried yield (mg)	6.8
50	LPS (mg)	19.8
	Sugar (mg)	3.1
	Protein (µg)	86
55	Nucleic acid (µg)	<161
	Purity (%)	96%

Table 2: 900814-2

5	Total dried yield (mg)	10.4
10	LPS (mg)	75.6
	Sugar (mg)	2.5
	Protein (μg)	64
15	Nucleic acid (μg)	<108
	Purity (%)	98<

Table 3: 900814-3

20	Total dried yield (mg)	19.2
25	LPS (mg)	103.6
	Sugar (mg)	7.6
	Protein (μg)	73
30	Nucleic acid (μg)	<137
	Purity (%)	99<

6) Molecular weight

The LPSs resulting from the respective cells were dissolved in distilled water, respectively to prepare solutions containing 2 mg/ml of LPSs. The 10 μl portions of the solutions were placed in 1.5 ml plastic tubes. To the respective portions there was added 10 μl of an SDS treatment solution prepared by mixing 10 μl of 10 % (w/v) of SDS, 45 μl of 5 % β-mercaptoethanol, 90 μl of a CBB coloring matter solution, 112.5 μl of 0.5 M Tris-HCl (pH 6.8) and 22.5 μl of distilled water. The resulting mixture was mixed well and then immersed in boiling water for 5 minutes, and immediately thereafter the mixture was quenched in ice water.

10 ml of 10 % (w/v) SDS, 17.9 g of tricine and 3.03 g of Tris were dissolved in 1 liter of distilled water to prepare a buffer solution for electrophoresis which was then placed in Slab-gel electrophoresis tank (Marisou Co.). 20 % polyacrylamide gel was fixed in the tank, and the sample was placed in the sample groove. The voltage was kept at 50 v for 1 hour, and then at 150 v, and the electrophoresis was allowed to proceed until the coloring matter flowed out through the gel; these procedures are defined as SDS-PAGE method throughout the specification and the claims. At the end of the electrophoresis, silver staining was carried out using silver staining kit 161-0443 (Bio-rad Co.) at room temperature to confirm the behavior.

The molecular weight of the LPSs of the present invention was calculated to be 5,000± 1,000 (LPS1 resulting from bacteria 900814-1), and 6,500± 2,500 (LPS2 and LPS3 resulting from bacteria 900814-2 and 900814-3, respectively) in view of the behaviors of the markers for protein m. w. [Pharmacia's LMW kit E: phosphorilase b (94k), albumin (67k), ovalbumin (43k), carbonic anhydrase (30k), trypsin inhibitor (20k), α-lactalbumin (14k)], and those of the markers for peptide m. w. [Pharmacia's 1860-101 m. w. marker: myoglobin (18.9k), myoglobin I & II (14.4k), myoglobin I (8.2k), myoglobin II (6.0k) and myoglobin IV (2.5k)]. In the same manner as the above, E. coli LPS (0127:B8LPS available from Difco Co.) was found to have dominant m. w. at 40,000± 10,000 and 8,000± 4,000.

The stained bands of LPS1, LPS2 and LPS3 in the silver staining are shown in Fig. 1. In Fig. 1, the number 1, 2 and 3 show the stained bands of LPS1, LPS2 and LPS3, respectively. As shown in Fig. 1, LPS1 showed another stained band around m. w. 30,000. LPS2 showed another stained band bridging from 30,000 to 43,000, but it may be said that it contains only little high molecular weight substance in view of the staining strength of the bands at 14,000 or less. Also in view of the sugar content and hexosamine content mentioned later, LPS2 the lowest sugar content, and LPS1 has higher sugar content than LPS3. This order is believed to be in harmony

with the patterns observed in the electrophoresis. Further, the ratio of LPS content to total dried yield decreases in the order of LPS2, LPS3 and LPS1. Considering the foregoing, it may be estimated that LPS2 comprises relatively low molecular weight LPSs, and the content of low molecular weight LPSs decrease in the order of LPS3 and LPS1.

5

#### 6) Phosphorus content

The captioned content was determined as follows according to the Chen-Toribara method (Chen et al., "Analytical Chemistry", vol. 28, pp. 1756 - 1758, 1956)

10

LPS1, LPS2 and LPS3 were dissolved in distilled water separately to prepare 20  $\mu\text{l}$  solutions containing 31.6, 57.6, or 103.6  $\mu\text{g}$  of LPS which were then placed in a small test tube. To the mixture there was added 20  $\mu\text{l}$  of 50 v/v sulfuric acid followed by heating at 160°C for 2 hours. Then 20  $\mu\text{l}$  of 50 v/v % perchloric acid was added to the mixture which was then heated on a gas burner for 1 minute to ash. Thereafter, 0.5  $\text{ml}$  of distilled water and then 0.5  $\text{ml}$  of a reaction reagent (a portion of the preparation made by mixing 1  $\text{ml}$  of 6N sulfuric acid, 2  $\text{ml}$  of distilled water, 2  $\text{ml}$  of 2.5 v/v % ammonium molybdate and 1  $\text{ml}$  of 10 v/v % of ascorbic acid) were added to the heated mixture which was then allowed to stand for 30 minutes at room temperature. Thereafter the absorption at 820nm ( $\text{OD}_{820\text{nm}}$ ) was determined. Here, as the standard sample for the preparation of the calibration curve, potassium didrogen phosphate (manufactured by Wako Jun-yaku Co. in Japan) was diluted with water to prepare 0.5  $\text{ml}$  of solutions containing 2.5  $\mu\text{g}$ , 1  $\mu\text{g}$ , 0.25  $\mu\text{g}$  or 0.1  $\mu\text{g}$  of phosphorus. In this connection, 1  $\text{g}$  of phosphorus corresponds to 4.39  $\text{g}$  of potassium didrogen phosphate. The effects observed are shown in Table 4 given below. In the table, the data of absorption are modified by subtracting the values of the control not subjected to the heating from the observed values in order to avoid occurrence of errors due to mixing-in of inorganic phosphorus from, for example, phosphate buffer solution. The P content ( $\mu\text{g}$ ) is calculated on the basis of the data of absorption. The P content (w/w %) was calculated according to the following equation. In the equation, "0.67" is the OD value of 1  $\mu\text{g}$  of the standard phosphorus, and the sample concentration is the proportion of the respective LPSs dissolved in distilled water (mg/ml).

15

20

25

$$\text{P content (w/w \%)} = \frac{\text{Absorption of sample}}{0.67 \times (\text{sample concentration}) \times 0.5}$$

P number is the number of phosphorus per m. w. 5,000 calculated according to the following equation:

30

$$\text{P number} = \frac{\text{P content (w/w \%)} \times 5,000}{100 \times 31}$$

35

Table 4

40

45

LPS	Absorption	P content ( $\mu\text{g}$ )	P content (w/w %)	P number
1	0.36	0.54	1.7	2 ± 1
2	0.31	0.46	0.8	1 ~ 2
3	0.87	1.30	1.3	2 ± 1

50

#### 8) Hexosamine content

The captioned content was determined as follows according to the Elson-Morgan method (Library of biochemical experiments. No. 4, pp. 377 - 379, Tokyo Kagaku Dojin Shuppan Co. in Japan).

55

LPS was dissolved in distilled water to prepare a solution containing 1.58 mg/ml of LPS1, 2.88 mg/ml of LPS2 or 5.18 mg/ml of LPS3, and the respective 100  $\mu\text{l}$  portions were placed in a test tube with a screwcap (manufactured by Iwaki Glass Co. in Japan) followed by addition of 100  $\mu\text{l}$  of 8N HCl thereto, and the mixture was heated at 110°C for 16 hours, and then about 200  $\mu\text{l}$  of 4N NaOH was added to the mixture to bring the pH to 7. A 100  $\mu\text{l}$  portion of the mixture was separated off and placed in another test tube with a screwcap fol-

lowed by addition of 200  $\mu\text{l}$  of Reagent A explained below thereto. The mixture was then heated at 105°C for 1.5 hours, and then cooled with a running water. Next, a 100  $\mu\text{l}$  portion of the mixture was separated off followed by addition of 670  $\mu\text{l}$  of a 96 % ethanol and then 67  $\mu\text{l}$  of Reagent B explained below, and was then allowed to stand at room temperature for 1 hour followed by determination of adsorption at 535nm. As the standard

5 sample to prepare the calibration curve, 0.20 - 200  $\mu\text{g/ml}$  of N-acetyl glucosamine (Wako Jun-yaku Co. in Japan) was used.

Reagent A: prepared by mixing 75  $\mu\text{l}$  of acetyl acetone and 2.5 ml of 1.25 N sodium carbonate

Reagent B: prepared by mixing 1.6g of p-dimethyl benzaldehyde, 30 ml of conc. hydrochloric acid and 30 ml of 96% ethanol

10 As a result, the number of hexosaDine in LPS1, LPS2 or LPS3 was 9  $\pm$  1, 7  $\pm$  1 or 5  $\pm$  1 per m. w. 5.000.

#### 9) KDO content

15 The KDO (2-keto-3-deoxyoctonate) content was determined as follows on the basis of the diphenylamine method (Shaby R. et al., "Analytical Biochem.", 58(1), pp. 123-129, 1974).

A KDO detection reagent was prepared by combining 500 mg of diphenylamine, 5 ml of ethanol, 45 ml of glacial acetic acid and 50 ml of conc. hydrochloric acid (all commercially available from Wako-junyaku Co. in Japan). A 500  $\mu\text{l}$  portion of the prepared reagent was combined with 250  $\mu\text{l}$  of distilled water containing any of 0.505 mg/ml of LPS1, 0.576 mg/ml of LPS2 and 0.518 mg/ml of LPS3. The resulting mixture was heated in a boiling water bath at 100°C for 33 minutes and then cooled in cooling water at 24.5°C for 30 minutes. The UV absorption of the mixture was determined at 420, 470, 630 and 650 nm to provide data  $A_{420}$ ,  $A_{470}$ ,  $A_{630}$  and  $A_{650}$ , respectively. As the standard sample, there was used 250  $\mu\text{l}$  of distilled water containing 0.5  $\mu\text{mole/ml}$  of ammonium salt of KDO (Sigma Co. in U.S.A.). The value S for the test and standard samples was calculated according to the following equation:

$$28 \quad S = A_{420} - A_{470} + A_{630} - A_{650}$$

The value of the test sample ( $S_t$ ) was 0.109 for LPS1, 0.078 for LPS2 and 0.099 for LPS 3, whereas that of the standard sample ( $S_s$ ) was 0.246. The value of distilled water was 0.005. The comparison of these values suggests that LPS1, LPS2 and LPS3 contain 2  $\pm$  1, 1-2 and 2  $\pm$  1 of KOD per m. w. 5,000.

30 As an example, in the case of LPS1, the KOD content of the solution x ( $\mu\text{mole/ml}$ ) may be determined by the equation:

$$\frac{0.5}{0.246} = \frac{x}{0.109}$$

According to the above equation, x is determined to be 0.221. Thus the molar number of KOD contained in 1 mole of LPS1 is determined to be 2.19 according to the following equation on the assumption that 1 mole of LPS1 is m. w. 5,000.

$$35 \quad y = x \times 10^{-6} \times \frac{5,000}{0.505 \times 10^{-3}} = 2.19$$

40 Illustrative embodiments of preparations containing LPS according to the present invention will be given in the following examples wherein the LPS content is in terms of E. coli LPS calculated according to the limulus test.

#### Example 2 (tablets)

45	Wheat LPS	0.04 g
	6% HPC lactose	178 g
50	Talc stearate	8 g
	Potato starch	14 g

The above ingredients were mixed and formed into 400 tablets each weighing 0.5 g and containing 0.1 mg of wheat LPS.

Example 3 (solution for internal use)

5	LPS1	1 mg
	Purified water	100 ml

Example 4 (ointment)

10	LPS1	0.1 g
	Purified lanolin	80 g
15	Yellow petrolatum	ad 1,000 g

Example 5 (injection)

20	LPS1	0.5 mg
	Distilled water for injection	ad 1,000 ml

Preparation 1 (preparation of B. pertussis LPS)

25 An experimental *B. pertussis* solution obtained from Serum Laboratory, a public institute of Chiba prefecture in Japan ( $2.0 \times 10^{10}$  cells / ml) was used.

The solution was suspended in sterile water to prepare a suspension containing 25 mg (dry basis) / ml of dead cells. To the suspension, there was added an equivalent of a 90% hot phenol solution (68 - 70°C) was added, and the mixture was shaken at 68°C for 1 hr. The mixture was subjected to centrifugation at 8,000 G, 4°C for 20 min. to collect the aqueous layer. Sterile water in the same quantity as of the aqueous layer was added to the remaining phenol, and the mixture was shaken in the same manner as the above. The resulting aqueous layer was combined with the first aqueous layer followed by dialysis in running water overnight, and then the mixture was concentrated to a tenth using a rotary evaporator. The concentrate was subjected to centrifugation at 8,000 G, 4°C for 20 min. The supernatant was separated off, and a small amount of sodium acetate was added thereto. Cold ethanol at 0 - 4°C was added to the mixture in an amount of six times as much as the latter, and the resulting mixture was allowed to stand at -20°C overnight. Then the mixture was subjected to centrifugation at 4,000 G, 4°C for 30 min. to collect the sediment which was subjected to centrifugal washing with ethanol (twice) and acetone (once) followed by drying with an aspirator. The residue was suspended in distilled water to prepare a 20 mg/ml of solution which was then subjected to ultrasonic treatment with a Sonifia 185 (Branson Co. in U.S.A.) (outlet control 5, 15 min., room temperature). The solution was subjected to centrifugation at 2,500 G, 4°C for 10 min. to separate off the supernatant.

40 The supernatant was treated at 4°C with nucleases, DNase I and RNase A (both manufactured by Sigma Co. in U.S.A) for 15 - 16 hrs; totally 10 µg/ml of DNase I and 20 µg/ml of RNase A were used. The same amount of the nucleases as the above were added to the mixture followed by warming at 37°C for 2 hrs and centrifugation at 2,500 G, 4°C for 10 min. to separate off the supernatant.

45 The supernatant was filtered through a pore size of 0.2 µm using Acrodisc manufactured by Gelman Co. in U.S.A. The filtrate was subjected to molecular sieve (resin: Sepharose 6B manufactured by Pharmacia Co. in U.S.A; column size: 5 cm (i.d.) x 100 cm (length); buffer: 10 mM of Tris-HCl / 10 mM of NaCl (pH 7.5); flow rate: about 3 ml/cm<sup>2</sup>/hr.). The fractions confirmed to be positive to limulus test with LS-1 kit commercially available from Sei-Kagaku Kogyo Co. in Japan were collected and filtered through a pore size of 0.2 µm using Acrodisc mentioned above. The filtrate was subjected to ion exchange (apparatus: FPLC manufactured by Pharmacia in U.S.A.; resin: mono Q HR 10/10 manufactured by Pharmacia in U.S.A.; buffer: 10 mM of Tris-HCl / 10 mM of NaCl (pH 7.5); flow rate: 2 ml/min.) wherein the filtrate was washed with the buffer for 15 min., then, after the NaCl content of the buffer was increased to 165 mM, for 30 min., then, for 20 min. while increasing the NaCl content to provide a NaCl content gradient from 165 mM to 1 M, and then, for 30 min. at the NaCl content of 1 M. The fractions confirmed to be positive to limulus test with LS-1 kit commercially available from Sei-Kagaku Kogyo Co. in Japan were collected.

The collected fractions were combined and desalted on a column (resin: Sephadex G-25 fine manufactured by Pharmacia in U.S.A.; column size: 2 cm (i. d.) x 25 cm (length); eluting agent: distilled water), and then lyophilized.

5 Nucleic acid is of the greatest possibility of being mixed in the lyophilized sample (4.50 mg). Therefore, the UV absorption curve (200 - 400 nm) was prepared, and the absorbance at 60 nm was determined.. The nucleic acid content was calculated to be 1% or less on the basis of the above absorbance in view of the fact that the nucleic acid content was 50 µg/ml in the case where the absorbance was 1. In addition, no apparent evidence showing the presence of a protein was observed in SDS electrophoresis. Thus, considering the detection sensibility, the highest content of proteins which may be mixed in the above lyophilized sample was estimated to be 0 - 3 %. Accordingly, the purity of the above lyophilized sample was estimated to be 96 % or more.

10 The physical properties of the thus prepared *B. pertussis* LPS (sometimes referred to only as *B. P.* LPS) were determined in the same manner as described in Example 1. The results were as follows:

Physical properties of *B. pertussis* LPS

15 Molecular weight: 6,000 ± 1,000 (by SDS-PAGE method)  
Phosphorus content: 4 per molecular weight of 6,000  
Hexosamine content: 12 per molecular weight of 6,000  
Fatty acid content: 4 per molecular weight of 6,000  
20 KDO content: 2 ± 1 per molecular weight of 6,000

The physical properties of *E. coli* LPS (0128: B8 manufactured by Difco Co. in U.S.A.) determined in the same manner as described in Reference Example 1 were as follows:

Physical properties of *E. coli* LPS

25 Molecular weight: 40,000 ± 10,000  
8,000 ± 4,000 (by SDS-PAGE method)  
Phosphorus content: 12 per molecular weight of 30,000  
Hexosamine content: 45 ± 6 per molecular weight of 30,000  
30 Fatty acid content: 18 per molecular weight of 30,000  
KDO content: 5 ± 1 per molecular weight of 30,000

Experiment 1 (immunity stimulating effects)

35 1) Zero point two ml of physiological saline containing 1, 10 or 100 µg (in terms of limulus activity) of LPS1, LPS2 or LPS3 was injected into 7 week old C3H/He male mice via caudal vein; each group consisted of two or three mice having an average weight of 25g. One hour later the serum was collected to determine the TNF activity on the basis of the toxicity to L929 cells. The results calculated as an average of two or three per group are shown in Table 5 given below. In the table, parenthesized are the number of the mice used.

40

45

50

55

Table 5

Dose	TNF activity (units/ml)		
	1 $\mu$ g	10 $\mu$ g	100 $\mu$ g
LPS1	6.15 (3)	25.80 (2)	30.69 (2)
LPS2	1.90 (3)	7.47 (2)	6.57 (2)
LPS3	7.44 (3)	16.19 (2)	34.47 (2)

Experiment 2 (analgesic effects)

To five-membered groups of 7 to 10 week old C3H/He male mice having an average body weight of 28 g, there was orally administrated 200  $\mu$ l of distilled water containing 0, 1, 5, 25 or 400  $\mu$ g / mouse of LPS3 or E. coli LPS using a probe. One and a half hours later, 500  $\mu$ l of 0.7 % acetic acid was given to the mice intraperitoneally over a period of 5 minutes. The frequency of writhing of the respective mice was counted, and the results as shown in Table 6 were recorded (an average of 5 mice in the respective groups). In the table, "-" reflects that the determination was not made at said dose. The writhing inhibition (%) was calculated by the following equation.

30 
$$\{1 - [( \text{frequency of writhing at the dose} ) - ( \text{that at } 400 \mu\text{g} )] / [ ( \text{frequency of writhing at } 0 \mu\text{g} ) - ( \text{that at } 400 \mu\text{g} ) ] \} \times 100$$

35

40

45

50

55

Table 6

LPS dose ( $\mu$ g/ mouse)	LPS3 of the present invention		E. coli LPS	
	Writhing frequency	Writhing inhibition (%)	Writhing frequency	Writhing inhibition (%)
0	18	0	20	0
1	17	10	18	82
5	10	80	-	-
25	7	110	13	64
400	8	100	9	100

Fig. 2 is a graph reflecting the results shown in Table 6. Fig. 2 shows that the writhing inhibition  $ED_{50}$  of LPS3 is 2.8  $\mu$ g / mouse, whereas that of E. coli LPS is 17  $\mu$ g / mouse. Thus it is supposed that the analgesic effect of LPS3 is about six times as of E. coli LPS.

#### Experiment 3 (Antiwithdrawal effect - 1)

Molecular sieves were impregnated with morphine HCl available from Takeda Chemical Industries Ltd. In Japan to prepare 12.7 mg of morphine pellet which was then implanted in the back, a little below the neck, of 4 to 5 week old ddY mice (body weight: 20 - 24 g). Two days later, there was given 50  $\mu$ g / kg of E. coli LPS (6 mice), LPS3 (7 mice) or B.P. LPS prepared in Preparation 1 (6 mice) as a solution in physiological saline.

The control group received only physiological saline. One hour later, 10 mg / kg of naloxone was given intraperitoneally, and immediately thereafter the jumping frequency of the mice was counted over a period of 40 minutes to determine the lumping control effects. The results are shown in Table 7. In the table, the figures show the number of the mice concerned. The lumping control effects were evaluated as follows:

The average lumping frequency of the control group (12 mice) per mouse was  $62.7 \pm 25.5$ . So, in view of the difference 37 (= 62.5 - 25.5), the case where the jumping frequency was 37 or more was estimated to have "no effect", whereas the case where the frequency was less than 37 was estimated to be "effective".

Table 7

	Jumping inhibition effect	
	Effective	No effect
Physiological saline	1	11
LPS3	7	0
E. coli LPS	3	3
B.P. LPS	4	2

As is apparent in Table 7, the antiwithdrawal Inhibition ratio was only about 8 % in the control group, whereas the value was 50 %, about 67 % or 100 % in the group to which E. coli LPS, B.P. LPS or LPS3 was given.

#### Experiment 4 (Antiwithdrawal effect - 2)

In order to determine whether the antiwithdrawal effects of the LPSs of the present invention in intravenous administration are dose-dependent, 12.7 mg of morphine pellet prepared as in Experiment 3 was implanted in the back, a little below the neck, of 4 to 5 week old ddY mice (average body weight: 20 g). Two days later, there was given 0.5 (to 6 mice), 5 (to 6 mice), 15 (to 9 mice), 50 (to 12 mice) or 500 µg / kg (to 6 mice) of LPS3 was given to the mice intravenously as a solution in physiological saline. The control group (10 mice) received only physiological saline. One hour later, 10 mg / kg of naloxone was given intraperitoneally, and immediately thereafter the jumping frequency of the mice was counted over a period of 40 minutes. The results are shown in Table 8 as an average per mouse in the respective groups.

Table 8

Dose of LPS3 (µg/kg)	0	0.5	5	15	50	500
Jumping frequency	69.5	36.8	42.0	16.1	20.5	11.5

Fig. 3 is a graph corresponding to the results given in Table 8.

#### Experiment 5 (Antiwithdrawal effect - 3)

In order to determine whether the antiwithdrawal effects of the LPSs of the present invention in intradermal administration are dose-dependent, the procedures of Experiment 4 were followed except that the dose of LPS3 was 50 (to 7 mice) or 500 µg / kg (to 5 mice), and the control group consisted of 8 mice. The results are shown in Table 9 as an average per mouse in the respective groups.

Table 9

Dose	Physiological saline	50 µg / kg	500 µg / kg
Frequency	84.7	44	19.8

Fig. 4 is a graph corresponding to the results given in Table 9.

Figs. 3 and 4 clearly show that the anti-withdrawal effects of the LPSs of the present invention are dose-dependent.

#### Experiment 6 (Antiwithdrawal effect - 4)

In order to determine whether the antiwithdrawal effects of the LPSs of the present invention are dose time-dependent, 12.7 mg of morphine pellet prepared as in experiment 3 was implanted in the back, a little below the neck, of 4 to 5 week old ddY mice (body weight: 20 - 24 g). Two days later, there was given 10 mg / kg of naloxone intraperitoneally. 50 µg / kg of LPS3 was administered to the mice 1 hour (7 mice), 3 hours (8 mice), 8 hours (6 mice) or 18 hours (5 mice) before the administration of naloxone. Immediately after the administration of naloxone, the jumping frequency of the mice was counted over a period of 40 minutes. The control group receiving no LPS3 consisted of 9 mice. The results are shown in Table 10 as an average per mouse in the respective groups.

Table 10

Administration time of LPS3	No dose	Hrs. prior to naloxone administration			
Jumping frequency	65.1	2.7	25.1	33.7	54.6

Fig. 5 is a graph corresponding to the results given in Table 10. Fig. 5 teaches that the LPSs of the present invention have withdrawal-preventive effects, and the maximal preventive effects will be shown when the LPSs are administered immediately before the occurrence of withdrawal symptoms.

#### Dose, interval and toxicity

In view of the nature of immunity stimulators, analgesics and withdrawal agents, and veterinary immunity stimulators, analgesics and withdrawal agents, the dose and the interval of the LPSs of the present invention are of course determined by the doctor or veterinarian in charge individually in view of the age, conditions, etc of the patient and effects of administration. However, it may be said that 1 µg - 100 mg (oral administration), 10 ng - 10 mg (intravenous administration) and 100 ng - 1 mg (percutaneous administration) are standard single dose per day to adults (body weight 60 kg). For veterinary use, about one sixtieth of the above quantities may be given per 1 kg of body weight of large-sized animals such as cattle, horses or the like. About twice as much

as the dose to large-sized animals may be given per 1 kg of body weight of medium- or small-sized animals such as pigs, dogs, cats or the like. Fowls or the like may receive twice as much as the dose to medium- or small-sized animals. The LD<sub>50</sub> of LPS1, LPS2 and LPS3 in 7 week old C3H/He male mice having an average body weight of 22 g were 150, 180 and 180 µg /mouse according to the Behrens Karber; these values are less than 60 % of 300 µg / mouse found for E. coli LPS. Further, E. coli LPS and B. P. LPS had the following LD<sub>50</sub> (an average of the data on two male BALB/C mice weighing 45 kg on average).

LPS	LD <sub>50</sub> / kg (mg)	
	i. v.	i. c.
E. coli LPS	3 . 4	1 6
B. P. LPS	1 1	3 2

20 **Claims**

## 1. LPS-producing gram-negative small bacilli having the following properties:

## a) Morphological characteristics

- 1) Small rod
- 2) No Motility
- 3) Gram stain: -

## b) Growth

- 1) Standard agar medium: a yellow to creamy round opaque colony is formed.
- 2) SS agar medium: A white translucent colony is formed.
- 3) TSI agar medium: No change is found on the slant, but the higher layer changes to yellow. Gas if produced.

## c) Physiological characteristics

- 1) Voges-Proskauer reaction: +
- 2) Indole production: -
- 3) Hydrogen sulfide production: -
- 4) Utilization of citrate: +
- 5) Urease: -
- 6) Oxidase: -
- 7) O-F test: +

## d) Utilization of carbon sources

- 1) Lactose: +
- 2) Adonitol: -
- 3) Rhamnose: +
- 4) Mannitol: +
- 5) Esculin: +
- 6) Inositol: -
- 7) Sorbitol: +
- 8) Arabinose: +
- 9) Raffinose: +
- 10) Sucrose: +

## e) Others

- 1) Lysin decarboxylase: -
- 2) Utilization of malonate: -
- 3) Arginine dihydroxylase: -
- 4) Phenylalanine deaminase: -
- 5) Ornithine decarboxylase: -

## 2. LPS-producing gram-negative small bacilli having the following properties:

5      a) Morphological characteristics  
      1) Small rod  
      2) No Motility  
      3) Gram stain: -

5      b) Growth  
      1) Standard agar medium: a creamy opaque colony is formed.  
      2) SS agar medium: A red opaque colony is formed.  
      3) TSI agar medium: No change is found on the slant, but

10     c) Physiological characteristics  
      1) Voges-Proskauer reaction: +  
      2) Indole production: -  
      3) Hydrogen sulfide production: -  
      4) Utilization of citrate: +  
      5) Urease: -  
15     6) Oxidase: -  
      7) O-F test: +

20     d) Utilization of carbon sources  
      1) Lactose: +  
      2) Adonitol: -  
20     3) Rhamnose: +  
      4) Mannitol: +  
      5) Esculin: +  
      6) Inositol: -  
      7) Sorbitol: +  
25     8) Arabinose: +  
      9) Raffinose: +  
      10) Sucrose: +

25     e) Others  
      1) Lysin decarboxylase: -  
30     2) Utilization of malonate: +  
      3) Arginine dihydrolase: +  
      4) Phenylalanine deaminase: -  
      5) Ornithine decarboxylase: +

35     3. LPS-producing gram-negative small bacilli having the following properties:  
a) Morphological characteristics  
      1) Small rod  
      2) No Motility  
      3) Gram stain: -

40     b) Growth  
      1) Standard agar medium: A yellow round translucent colony is formed.  
      2) SS agar medium: No colony is formed.  
      3) TSI agar medium: No change is found on the slant, but the higher layer changes to yellow. Gas is not produced.

45     c) Physiological characteristics  
      1) Voges-Proskauer reaction: +  
      2) Indole production: -  
      3) Hydrogen sulfide production: -  
      4) Utilization of citrate: +  
      5) Urease: -  
50     6) Oxidase: -  
      7) O-F test: +

55     d) Utilization of carbon sources  
      1) Lactose: +  
      2) Adonitol: -  
      3) Rhamnose: +  
      4) Mannitol: +  
      5) Esculin: +

6) Inositol: -  
7) Sorbitol: +  
8) Arabinose: +  
9) Raffinose: -  
5 10) Sucrose: +  
e) Others  
1) Lysin decarboxylase: -  
2) Utilization of malonate: +  
3) Arginine dihydrolase: -  
10 4) Phenylalanine deaminase: -  
5) Ornithine decarboxylase: -

4. LPS provided by the bacilli of Claim 1 and exhibiting the dominant molecular weight of  $5,000 \pm 1,000$  as determined by SDS-PAGE method, having  $2 \pm 1$  phosphorus,  $9 \pm 1$  hexosamines and  $2 \pm 1$  KDO per molecular weight of 5,000.  
15

5. LPS provided by the bacilli of Claim 2 and exhibiting the dominant molecular weight of  $6,500 \pm 2,500$  as determined by SDS-PAGE method, having 1 - 2 phosphorus,  $7 \pm 1$  hexosamines and 1 - 2 KDO per molecular weight of 5,000.  
20

6. LPS provided by the bacilli of Claim 3 and exhibiting the dominant molecular weight of  $6,500 \pm 2,500$  as determined by SDS-PAGE method, having  $2 \pm 1$  phosphorus,  $5 \pm 1$  hexosamines and  $2 \pm 1$  KDO per molecular weight of 5,000.  
25

7. An immunity stimulator containing LPS selected from the group consisting of the LPSs of Claims 4 - 6 and mixtures thereof.  
8. An analgesic containing LPS selected from the group consisting of the LPSs of Claims 4 - 6 and mixtures thereof.  
30

9. An antithrombotic agent containing LPS selected from the group consisting of the LPSs of Claims 4 - 6 and mixtures thereof.  
35

10. A veterinary immunity stimulator containing LPS selected from the group consisting of the LPSs of Claims 4 - 6 and mixtures thereof.  
11. A veterinary analgesic containing LPS selected from the group consisting of the LPSs of Claims 4 - 6 and mixtures thereof.  
40


12. A veterinary antithrombotic agent containing LPS selected from the group consisting of the LPSs of Claims 4 - 6 and mixtures thereof.

45


50

55


F I G . 1




F I G . 2



F I G . 3



F I G . 4



F I G . 5

